BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23925926)

  • 1. The effect of a Rapid Access Prostate Cancer Clinic on prostate cancer patient and disease characteristics, primary treatment and surgical workload.
    Oon SF; Cullen IM; Moran D; Bolton EM; McDermott T; Grainger R; Lynch TH
    Ir J Med Sci; 2014 Jun; 183(2):241-7. PubMed ID: 23925926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid access diagnostic clinic for prostate cancer: the experience after one year.
    Forde JC; O'Connor KM; Casey L; O'Brien M; Bowen S; Casey RG; Ahmed I; McDermott TE; Grainger R; Lynch TH
    Ir J Med Sci; 2011 Jun; 180(2):505-8. PubMed ID: 21293947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Rapid Access Prostate Clinics on the outcomes of Gleason 7 prostate cancer: does earlier diagnosis lead to better outcomes?
    Broe MP; Forde JC; Inder MS; Galvin DJ; Mulvin DW; Quinlan DM
    Ir J Med Sci; 2017 Aug; 186(3):583-588. PubMed ID: 28281040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging evidence for Gleason grade migration and distance impact in prostate cancer? An analysis of the rapid access prostate clinic in a tertiary referral center: St. Vincent's University Hospital, Dublin (2009-2011).
    O'Kelly F; Thomas AZ; Murray D; Lee P; O'Carroll RF; Nicholson P; Forristal H; Swan N; Galvin D; Mulvin D; Quinlan DM
    Ir J Med Sci; 2013 Sep; 182(3):487-91. PubMed ID: 23417241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audit of rapid access introduction reveals high prevalence of prostate cancer in Western Region.
    Bolton EM; Kelly BD; Quinlan MR; D'Arcy FT; Azar M; Dowling CM; Power M; McCarthy P; Roche C; Walsh K; Rogers E; Durkan GC
    Ir J Med Sci; 2014 Jun; 183(2):173-9. PubMed ID: 23868288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gleason inflation 1998-2011: a registry study of 97,168 men.
    Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
    BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
    Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
    World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
    Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.